Neostem Receives New Coverage from Analysts at Aegis

The firm set a "buy" rating and a $2.50 price target on the stock. Aegis' target price indicates a potential upside of 391.16% from the company's current price.

http://www.americanbankingnews.com/2013/06/24/aegis-initiates-coverage-on-neostem-nbs/